Bombshell Study Exposes FDA Abortion Pill Cover

FDA building sign with blue sky background

A bombshell new study has pro-life medical experts demanding that RFK Jr. and the FDA finally confront the real dangers of abortion pills, revealing that the actual rate of serious complications is over twenty times higher than what Americans have been told for decades.

At a Glance

Insurance data shows a 10.93% rate of serious complications from abortion pills—over 22 times the rate previously claimed by the FDA.
Pro-life medical groups are calling on HHS Secretary RFK Jr. and FDA chief Dr. Marty Makary to review and possibly revoke the drug’s approval.
Political leaders and advocacy groups are demanding transparency and stronger protections for women’s health.
The FDA has pledged a full review, but the future of mifepristone access and regulation hangs in the balance.

Pro-Life Doctors Sound the Alarm: Abortion Pill Dangers Far Worse Than Admitted

For more than two decades, Americans have been told by federal health agencies and abortion advocates that abortion pills are “safer than Tylenol.” Now, pro-life medical organizations are blasting that tired refrain as pure fantasy, armed with real-world data that exposes a disturbing truth: the risks of mifepristone may have been covered up or downplayed from the start. The FDA greenlit mifepristone in 2000 after reviewing clinical trials that claimed less than 0.5% of women would suffer serious adverse reactions. But a massive new insurance claims study covering nearly 900,000 medication abortions from 2017 to 2023 found a whopping 10.93% rate of serious complications, including sepsis, hemorrhaging, and life-threatening infections. That’s 22 times the risk that’s still on the label and what millions of women have heard from their doctors and the media.

The American Association of Pro-Life OBGYNs and five other physician groups are now demanding that HHS Secretary Robert F. Kennedy Jr. and FDA Administrator Dr. Marty Makary revisit the agency’s original approval of mifepristone, citing an ethical and legal obligation to ensure women have truthful information about the risks they face. Lawmakers like Senator Steve Daines have joined the calls for action, warning that the FDA cannot keep ignoring mounting evidence of harm. In a letter to RFK Jr. and Dr. Makary, the coalition insists that the FDA must reinstate strict safety protocols and require full reporting of every complication—not just the handful that drug makers bother to mention.

FDA Under Pressure: Will Kennedy and Makary Protect Women—Or Big Pharma and Abortion Politics?

The FDA’s credibility is on the line. For years, critics have attacked the agency for allowing political pressure and activist lobbying to trump actual science, especially when it comes to abortion. Under the Biden administration, the FDA scrapped crucial safety measures and allowed abortion pills to be shipped by mail, a move celebrated by the abortion lobby but condemned by doctors who treat the aftermath. Now, RFK Jr.—famous for his supposed “skepticism” of corporate influence and government overreach—sits at the center of this firestorm. Will he side with the medical establishment and abortion industry, or demand an honest reckoning with the facts?

Dr. Makary, the new FDA chief, has at least promised a “complete review.” But that’s cold comfort to the women who’ve already suffered, and to the families devastated by complications that were supposedly “rare.” Pro-life experts point out that the FDA’s own drug safety reporting system is riddled with loopholes, allowing drug makers and abortion providers to hide or ignore thousands of adverse outcomes. The new insurance claims study, by contrast, doesn’t rely on self-reporting or politically motivated “studies.” It simply tracks real women’s hospital visits, surgeries, and life-threatening emergencies after taking mifepristone. The results are impossible to spin away.

What’s Next: Will the FDA Finally Listen—Or Keep Sacrificing Truth for Ideology?

The stakes are enormous. If the FDA admits the risks are as high as the EPPC study claims, it could mean the end of mail-order abortion pills and a return to in-person doctor visits, ultrasounds, and real informed consent. The abortion industry and its political allies are already scrambling to discredit the study, arguing that insurance data “overestimates” risk or fails to account for unrelated health problems. But pro-life physicians and lawmakers aren’t buying it. They see a government agency so obsessed with “access” and “equity” that it’s willing to gamble with women’s health, all in the name of a political agenda.

Women deserve better than propaganda and stonewalling from the very regulators meant to protect them. As the FDA begins its review, the American public is watching closely. Will RFK Jr. and Dr. Makary finally put science and common sense above ideology? Or will they keep bowing to the radical abortion lobby—no matter how many women pay the price?